Avadel Pharmaceuticals plc (AVDL)
| Market Cap | 2.25B |
| Revenue (ttm) | 248.52M |
| Net Income (ttm) | -278,000 |
| Shares Out | 97.66M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | 32.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,905,178 |
| Open | 23.25 |
| Previous Close | 23.56 |
| Day's Range | 22.86 - 23.36 |
| 52-Week Range | 6.38 - 23.57 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 18.06 (-21.55%) |
| Earnings Date | Nov 4, 2025 |
About AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. [Read more]
Financial Performance
In 2024, Avadel Pharmaceuticals's revenue was $169.12 million, an increase of 504.79% compared to the previous year's $27.96 million. Losses were -$48.83 million, -69.53% less than in 2023.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AVDL stock is "Buy." The 12-month stock price target is $18.06, which is a decrease of -21.55% from the latest price.
News
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of Nov. 17, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
Avadel Receives Unsolicited Proposal from Lundbeck
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR...
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER ...
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to ...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
3 Biopharma Names I Am Buying After Avadel's Buyout
M&A activity has seen a notable pick-up in the biotech/biopharma industries over the past six weeks. This rise in deal volume has resulted in a nice rally in the sector, which has been a long-term lag...
Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Alkermes to acquire Avadel for up to $2.1 billion
Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement
DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settle...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of ...
Avadel: Mispriced Leader In Once-Nightly Sleep Therapies
Avadel Pharmaceuticals is deeply undervalued, with LUMRYZ and Valiloxybate offering $2B+ peak sales potential in sleep disorders. AVDL's once-at-bedtime Oxybate franchise is clinically superior, paten...
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept.
Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating
Avadel's stellar 2024 performance is driven by LUMRYZ's strong revenue growth, positive net income, and robust patient demand. The $20M global licensing deal for valiloxybate diversifies Avadel's pipe...
Avadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Thomas McHugh - Senior VP, Principal Financial & Ac...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REF...
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of m...
Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Gregory J. Divis - CEO & Director Susan Rodriguez - Chief Operating Officer Th...
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June ...